Covance, Frenova Renal Research collaborate
Covance, a Princeton, N.J.-based global drug development services company, and Frenova Renal Research, a Fresenius Medical Care North America (FMCNA) company based in Waltham, Mass., have announced a new research collaboration designed to find more effective treatments for patients living with chronic kidney disease (CKD) and end stage renal disease (ESRD).
This collaboration enables Covance to use its analytics capabilities to conduct research on behalf of its biopharmaceutical clients using Frenova’s database, a renal database with longitudinal data on more than 393,000 CKD patients and 980,000 ESRD patients. The goal is to improve the lives of kidney patients by looking at which treatments are most effective.
The data will be used to better understand the burden of illness, treatment patterns, medication adherence and comparative safety and efficacy of medical treatments in the real world. The collaboration also will help new drug sponsors assess protocol feasibility, select study sites, conduct targeted patient recruitment and determine optimal sample size.
Marc Ginsky, vice president and general manager for Covance Market Access Services, said, “Not only will this better inform treatment and care guidelines, but it has the potential to also inform clinical trial design and drug development.”
This new collaboration has significant potential to support all key stakeholders, but especially dialysis patients, who undergo intensive treatment three days a week and whose average life expectancy after diagnosis is five years. The ultimate goal is for the analyses to provide insights into ways of slowing the progression of chronic kidney disease and preventing the need for dialysis for some patients altogether.
“With this unique combination of data and analytics, we can look at how patients actually use medicines day-to-day, which includes the reality of less-than-perfect adherence,” Ginsky said. “We can then explore real-world safety and effectiveness, comparing therapies head-to-head and in the full range of patients, not just those who meet narrow inclusion and exclusion criteria.”